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ABSTRACT
Intensive chemotherapy for human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL)
and Hodgkin lymphoma (HL) has resulted in durable remissions in a substantial proportion of patients.
High-dose chemotherapy and autologous stem cell transplantation (AuSCT), moreover, has resulted in
sustained complete remissions in selected patients with recurrent chemosensitive disease. Based on a favorable
experience with dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT for older patients with non-
HIV–associated aggressive lymphomas, an AIDS Malignancy Consortium multicenter trial was undertaken us-
ing the same dose-reduced busulfan and cyclophosphamide preparative regimen with AuSCT for recurrent
HIV-associated NHL and HL. Of the 27 patients in the study, 20 received an AuSCT. The median time to
achievement of an absolute neutrophil count (ANC) of$ 0.5109/L was 11 days (range, 9-16 days). The median
time to achievement of an unsupported platelet count of$ 20109/Lwas 13 days (range, 6-57 days). One patient
died on day 133 posttransplantation from hepatic veno-occlusive disease (VOD) and multiorgan failure. No
other fatal regimen-related toxicity occurred. Ten of 19 patients (53%) were in complete remission at the
time of their day 1100 post-AuSCT evaluation. Of the 20 patients, 10 were alive and event-free at a median
of 23 weeks post-AuSCT. Median overall survival (OS) was not reached by 13 of the 20 patients alive at the
time of last follow-up. This multi-institutional trial demonstrates that a regimen of dose-reduced high-dose
busulfan, cyclophosphamide, and AuSCT is well tolerated and is associated with favorable disease-free survival
(DFS) and OS probabilities for selected patients with HIV-associated NHL and HL.
 2008 American Society for Blood and Marrow Transplantation
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High-dose chemotherapy and autologous stem cell
transplantation (AuSCT) is the treatment of choice for
relapsed, chemotherapy-sensitive, and aggressive or
highly aggressive non-Hodgkin lymphoma (NHL)
and Hodgkin lymphoma (HL) [1,2]. The prospective
randomized Parma trial found improved survival out-
comes in patients with recurrent NHL who received
an autologous bone marrow transplant (BMT) com-pared with those who received additional conventional
salvage chemotherapy [1]. Two other prospective
randomized trials also demonstrated improvements
in progression-free survival (PFS) for patients with re-
current HL who received AuSCT compared with
those who received chemotherapy alone [3,4].
NHL occurring in association with human immu-
nodeficiency virus (HIV) infection usually has an
aggressive or highly aggressive histology [5-7].59
60 T. R. Spitzer et al.Historically, patients with HIV-associated NHL have
fared poorly in terms of both insufficient control of
lymphoma and substantial comorbidity compromising
their ability to receive optimal chemotherapy. With
the advent of highly active antiretroviral therapy
(HAART) and the increasing diagnosis of HIV-associ-
atedNHL in patients without other AIDS-defining ill-
nesses, more aggressive antilymphoma treatment,
including AuSCT for patients in relapse, has been
evaluated [8-12]. Selected patients with a relatively
low HIV RNA viral load (HIV VL) but no history of
recent opportunistic infections may achieve durable
disease control after either primary therapy or AuSCT
for recurrent disease [13-16].
AlthoughHL is not an AIDS-definingmalignancy,
the incidence is increased in patients with HIV infec-
tion [11,17]. Durable PFS is also possible with aggres-
sive multiagent chemotherapy for HIV-associated
HL. Less well studied is the role of AuSCT for treating
recurrent HIV-associated HL [13].
The optimal preparative therapy for AuSCT for
NHL and HL is uncertain. Given the likely increased
risk of transplantation-related complications in older
patients and patients with significant comorbidity,
such as HIV infection, regimens have been designed
to minimize regimen-related toxicity (RRT), whereas
still delivering adequate cytoreductive therapy. In an
effort to reduce RRT for AuSCT and expand autolo-
gous transplantation applications to older patients
than have historically been treated, we designed
a dose-reduced busulfan (BU) and cyclophosphamide
(CY) preparative regimen for AuSCT. This regimen
consisted of the administration of 14 mg/kg of oral
or, more recently, 11.2 mg/kg of intravenous (IV)
BU with 120 mg/kg of CY for patients age 50 years
and older [18]. This regimen has been well tolerated
in patients up to age 78, and favorable PFS and overall
survival (OS) outcomes have been observed compared
with patients under age 50 who received 16 mg/kg of
oral BU. Based on this encouraging experience, we de-
signed a pilot evaluation of dose-reduced BU and CY
as preparative therapy for AuSCT for treating HIV-
associated NHL and HL.
PATIENTS AND METHODS
Twenty-seven patients with HIV-associated NHL
or HL were enrolled in a multicenter AIDS Malig-
nancy Consortium (AMC) trial sponsored by the Na-
tional Cancer Institute. Institutional review board
approval was obtained at each participating institution
for the conduct of the trial. Written informed consent
was obtained from all patients.
Eligibility criteria for transplantation included
HIV-1 infection confirmed by Western blot or a de-
tectable HIV VL, a CD41 count . 50 cells/mL, an
HIVVL\110,000 copies/mL, a diagnosis of interme-diate or high-gradeNHL orHL, and failure to achieve
complete remission (CR) with initial therapy or relapse
after initial therapy. Patients were required to have
a Karnofsky performance status . 60% and to have
lymphoma that was sensitive to their most recent che-
motherapy regimen, as defined by an improvement in
bidimensional tumor measurements of at least 25% or
an improvement in evaluable disease sustained over 4
weeks. Exclusion criteria included the presence of an
active opportunistic infection, serum creatinine of .
2.0 mg/dL and significant organ dysfunction (eg, left
ventricular ejection fraction\45% or diffusing capac-
ity of the lung for carbon monoxide\ 60% of pre-
dicted), AST . 3 times the upper limits of normal,
bilirubin . 2.0 mg/dL (unless the patient’s hyperbili-
rubinemia was ascribed to antiretroviral therapy),
and active leptomeningeal or parenchymal central
nervous system (CNS) lymphoma. The patient’s
demographic profiles and baseline HIV disease char-
acteristics, including CD41 cell count, HIV VL, and
lymphoma histopathology, are given in Table 1. Indi-
vidual patient characteristics, including International
Prognostic Index (IPI), number of previous chemo-
therapy regimens, and remission status at transplanta-
tion, are given in Table 2. Fifteen patients had NHL;
12 had diffuse large B cell, B cell anaplastic, or
immunoblastic lymphoma; and 3 had Burkitt or atyp-
ical Burkitt lymphoma, according to the Revised
European-American Lymphoma–World Health Or-
ganization classification of NHL [19]. Five patients
had HL, 3 of whom had mixed cellularity histology.
All of the patients who underwent transplantation
were male.
Stem Cell Mobilization
For stem cell mobilization, patients received CY
3000 mg/m2 with hydration and mesna 15 mg/kg
before and 3, 6, and 9 hours after CY for uroprotec-
tion, or an alternative salvage chemotherapy to which
the lymphoma was responding. Granulocyte colony-
stimulating factor (G-CSF) was administered at
a dose of 10 mg/kg/day beginning 2 days after chemo-
therapy. Once the white blood count (WBC) was $
0.5  109/L, leukapheresis was performed a maximum
of 4 times until an intended number of 2 106 CD341
cells/kg were collected.
Transplantation Preparative Therapy
Four patients received oral BU at a dose of 1 mg/kg
every 6 hours for a total of 14 doses, and 16 patients re-
ceived IV BU at a dose of 0.8 mg/kg every 6 hours for
a total of 14 doses. Phenytoin 400 mg daily was given
prophylactically to prevent seizures. CY 60 mg/kg/day
was given i.v. on transplantationdays23 and22.Mesna
15 mg/kg 15 minutes before and 3, 6, and 9 hours after
CY was given on days23 and22. For patients. 20%
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calculated based on a weight 50% between the patient’s
actual weight and ideal body weight.
Stem Cell Infusion
Autologous peripheral stem cells were thawed in
a 37C water bath and infused through the patient’s
central venous catheter on transplantation day 0. A
median infusion of 4.62  106/kg CD341 cells (range,
1.53-6.34  106/kg) was administered.
Table 1. Patient and baseline disease characteristics
Characteristic n
Patients receiving AuSCT 20
Male:female ratio 20:0
Race/ethnicity
White 14
Black 2
Hispanic 4
Median age, years (range) 42 (33-60)
CD41 cell count, cells/mL, baseline
median (range)
203 (53-574)
HIV viral load, copies/mL, baseline
median (range)
317 (50-5712)
Lymphoma histology
NHL 15
DLBCL 8
Immunoblastic 3
Anaplastic B cell 1
Burkitt/atypical Burkitt 3
HL 5
Mixed cellularity 3
Nodular sclerosis 1
Not specified 1
DLBCL, diffuse large B cell lymphoma.Concurrent Therapies
CNS Prophylaxis. Patients with NHL received
a single 50-mg dose of intrathecal cytosine arabinoside
before conditioning at the time of diagnostic lumbar
puncture.
Anti-InfectionProphylaxis. All patients received tri-
methoprim-sulfamethoxazole (TMP-SMX)-DS (dou-
ble strength) every other day during the preparative
therapy. TMP-SMX-DS was held from the day of
stem cell infusion (day 0) until engraftment. Patients
who were allergic to or intolerant of TMP-SMX re-
ceived alternative Pneumocystis jiroveci pneumonia
(PCP) prophylaxis with dapsone or atovaquone. PCP
prophylaxis was continued for a minimum of 3 months
and was discontinued only if the CD41 count exceeded
200 cells/mL. Fluconazole 200mg daily (or another sys-
temic antifungal agent of the investigator’s choice) was
begun during preparative therapy and was continued
for up to 6 months posttransplantation.
Antiretroviral therapy, including a combination of
2 nucleoside analogs and 1 or 2 protease inhibitors, was
continued (or initiated before stem cell harvesting) as
tolerated. Ritonavir was not incorporated into the
HAART regimen because of its unpredictable hepatic
p450 effects on drug metabolism, and zidovudine was
not incorporated into the HAART regimen because
of its potential myelosuppressive effects.
All blood products were leukocyte-reduced using
third-generation leukocyte filters, and irradiated
(2500 cGy) from a 137/Cs irradiator to prevent trans-
fusion-associated graft-versus-host disease (GVHD).
G-CSF was given at a dose of 5 mg/kg i.v. orTable 2. Baseline patient characteristics
Patient Age, years Disease IPI score
Previous
chemotherapy regimens
Remission status at
transplantation
1 41 HD NA 3 CR
2 36 SNCL 3 3 CR
3 34 HD NA 2 CS
4 47 DLBCL 1 2 PR
5 51 DLBCL 2 2 PR
6 43 SNCL 2 3 CS
7 43 DLBCL 2 2 CS
8 38 DLBCL 1 2 CS
9 43 SNCL 1 3 CS
10 50 B cell immunoblastic 1 3 CS
11 36 B cell immunoblastic 3 2 CS
12 64 HD NA 3 CS
13 42 Anaplastic B cell 4 2 CS
14 37 DLBCL 3 2 CS
15 39 DLBCL 1 3 CR
16 44 DLBCL 1 2 CR
17 36 B cell immunoblastic 2 2 CS
18 33 HD NA 2 CR
19 37 HD NA 2 CR
20 55 DLBCL 0 2 CS
IPI indicates International Prognostic Index; CS, chemotherapy sensitive (as defined in Patients andMethods); DLBCL, diffuse large B cell lym-
phoma; SNCL, small noncleaved cell (Burkitt/atypical Burkitt) lymphoma; NA, not applicable.
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ued until the WBC count was $ 10  109 /L.
Evaluation of Response
All patients were assessed by physical examination
and repeat imaging studies for response at approxi-
mately 3 months posttransplantation, then every 3
months during the first year and every 6months during
the second year. Response criteria were according to
the established guidelines for lymphoma response
evaluation [20].
Measurement of CD41 Cell Levels and HIV VL
CD41 cell counts and HIV VL evaluation were
scheduled for days 114 and 121 and months 1, 2, 3,
6, 9, and 12 post-AuSCT. The assays were performed
at each participating institution.
Statistical Methods
This study was designed to assess the safety and
tolerability of intensive chemotherapy and AuSCT
for the treatment of HIV-related NHL and HL. A
minimum of 4 and a maximum of 25 patients were to
be treated on this protocol The study would have
been stopped had the number of transplantation-re-
lated deaths exceeded the number expected with an un-
derlying mortality rate from transplantation of 20%.
All deaths occurring within 30 days of transplantation
were considered transplantation-related.
Summary statistics were used to describe the de-
mographic features and baseline characteristics of the
study population. The binomial proportion and its
95% confidence interval were used to estimate the re-
sponse at 100 days posttransplantation. The Kaplan-
Meier method was used to describe the distribution
of OS and event-free survival.
RESULTS
Of the 27 patients enrolled in the study, 20 re-
ceived an AuSCT. Seven patients did not receive an
AuSCT, because of inadequate stem cell collection
(n 5 2), early disease progression (n 5 4), or cardiac
dysfunction (n 5 1).
Engraftment
The median time to achievement of an absolute
neutrophil count (ANC) $ 0.5  109 /L was 11 days
(range, 9-16 days). Among the 18 evaluable patients
(1 patient never achieved a platelet count of .
20109/L, and 1 had not recovered his platelet count
by the time of his death on day 133), the median
time to achievement of an unsupported platelet count
of $ 20109/L was 13 days (range, 6-57 days).Toxicities
One patient developed rapidly rising transaminase
levels post-AuSCT. A liver biopsy on day112 showed
hepatic veno-occlusive disease (VOD). On day 114,
defibrotide was initiated, but progressive multiorgan
failure ensued. Despite aggressive medical care, in-
cluding intubation and mechanical ventilation, he ex-
pired on day 133 post-AuSCT.
No other fatal regimen-related toxicity occurred.
No patient developed grade III or IV nausea or vomit-
ing. Five patients developed oropharyngeal mucositis
(4 grade I-II, 1 grade III). Six patients experienced fe-
brile neutropenia. Four patients had a documented
bacteremia# 100 days post-AuSCT (3 coagulase-neg-
ative staphylococcus, 1 pleomorphic Gram-negative
rod). Other infections occurring within 100 days
post-AuSCT included Clostridium difficile colitis
(n5 3), cytomegalovirus (CMV) infection (n5 4), her-
pes simplex virus (HSV) infection (n 5 1) and Entero-
coccus faecalis urinary tract infection (n 5 1). Other
nonhematologic grade III-IV toxicities (# 100 days
post-AuSCT) are listed in Table 3.
Response Rates and Survival
Of the 20 patients who received an AuSCT, only 1
early transplantation-related death occurred (from he-
patic VOD on day 133 post-AuSCT). Ten of the 19
evaluable patients (53%) were in CR at the time of
their day 1100 staging evaluation. Because only 3 pa-
tients with HL were evaluable for response (1 patient
in CR), it was not possible to analyze the HL and
NHL patients separately with respect to antitumor ef-
ficacy. Nine patients exhibited progression of disease
by day 1100 post-AuSCT. Of the 20 patients, 10
were alive and event-free at a median of 23 weeks
post-AuSCT (range, 4-1201 weeks) (Figure 1).
Median OS had not been reached, with 13 of 20
patients alive at the time of last follow-up (Figure 1).
Table 3.Nonhematologic grade III-IV toxicities (#100 days post-AuSCT)
Toxicity n
Stomatitis/pharyngitis 1
Febrile neutropenia 6
Documented infection* 12
Metabolic† 5
Headache/other pain 3
Thromboembolism 1
Thrombotic
microangiopathy
1
Hemorrhage 4
Mental status change 2
*Bacteremia (n 5 4), Clostridium difficile colitis (n 5 3), herpes sim-
plex skin infection (n5 1), cytomegalovirus infection (n5 3), Entero-
coccus faecalis urinary tract infection (n 5 1).
†Hyperuricemia (n 5 1), hyperkalemia (n 5 1), hypermagnesemia
(n 5 1), hypophosphatemia (n 5 1), other (n 5 1).
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plantation are 49.5% and 74.4%, respectively.
CD41 Cell Counts and HIV VL after ASCT
No consistent temporal trend can be seen with re-
spect to the available CD41 counts and HIV VLs, and
significant interpatient variability exists with respect to
these measures (Figure 2). Thus, the conditioning reg-
imen did not appear to have a consistent effect on these
measures of HIV activity. The variability in these mea-
sures may reflect the use of different HAART regi-
mens based on the investigator’s discretion (ie, not
mandated by the protocol) and that there was substan-
tial variability in how well these regimens suppressed
HIV viremia.
DISCUSSION
The indications for AuSCT for treating HIV-
infected patients with relapsed NHL and HL but
with HAART options and no active opportunistic in-
fection are becoming increasingly clear. The present
multi-institutional clinical trial demonstrates that
AuSCT in this patent population is safe and is associ-
ated with potent antitumor effects. Several pilot stud-
ies using high-dose chemotherapy followed by AuSCT
for recurrent or refractory NHL or HL also have eval-
uated the safety and efficacy of AuSCT for HIV-asso-
ciated lymphoma (Table 4). Krishnan et al. [13] from
City of Hope described 20 patients who received
AuSCT for recurrent or refractory HIV-associated
NHL or HL. Conditioning therapy consisted of CY,
carmustine, and etoposide, or, for patients under age
55 without previous radiation therapy, total body irra-
diation (TBI), CY, and etoposide. The PFS and OS
probabilities were 85% at a median posttransplanta-
tion follow-up of 31.8 months. Gabarre et al. [15] de-
scribed the outcomes after AuSCT in 14 patients with
HIV-associated NHL or HL. Five patients were alive,
4 of whom were disease-free at 14-49 months post-
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Figure 1. Event-free survival (EFS) and OS (median OS not yet
reached) at a median of 23 weeks post-AuSCT.transplantation. No transplantation-related deaths oc-
curred. Re et al. [16] treated 16 patients with
HIV-associated NHL or HL with high-dose BCNU,
etoposide, cytosine arabinoside, and melphalan
(BEAM) chemotherapy and AuSCT. No transplanta-
tion-related deaths occurred. Six patients were alive
and disease-free at a median of 8 months posttrans-
plantation. Serrano et al. [14] described the outcomes
of 11 patients with HIV-associated lymphoma who re-
ceived high-dose chemotherapy and AuSCT. Eight
patients were alive in CR at a median of 30 months
after AuSCT. CD41 cell count reconstitution while
patients continued to receive HAART was well dem-
onstrated, and there was no clear evidence of worsen-
ing underlying HIV infection. Moreover, in vitro
studies of immune reconstitution by Benicchi et al.
[21], including analysis of interleukin-7 levels, T cell
subsets, and T cell V-beta repertoires, in 4 patients
who underwent AuSCT demonstrated no worsening
of immune deficits in this patient population.
High-dose BU and CY as preparative therapy for
AuSCT has been most widely evaluated in the treat-
ment of myeloid malignancies [22,23]. Originally ad-
ministered in its oral form, BU has highly variable
absorption and pharmacokinetics, making the severity
of RRT difficult to predict. With pharmacokinetic
analyses designed to limit exposure to excessively
high drug concentrations, a decreased incidence of se-
vere RRThas been observed [24].Moreover, achieving
targeted area under the curve (AVC) drug concentra-
tion has been shown to correlate with a reduced
incidence of recurrence of some hematologic malig-
nancies (eg, chronic myeloid leukemia) [25]. IV BU is
associated with a much more narrow and predictable
pharmacokinetic profile and has been associated with
a lower incidence of hepatic VOD and other severe
RRTs compared with preparative regimens using oral
BU [26-29]. BU and CY as preparative therapy for
AuSCT for NHL and HL is an active (albeit not as
well-studied) regimen [30-32]. There are no convinc-
ing data to support a correlation between BU levels
and toxicity or freedom from relapse in this population.
The choice of reduced-dose BU and CY as prepar-
ative therapy for AuSCT was based on a favorable
experience with this regimen in older patients with
non-HIV–related malignancies undergoing transplan-
tation [18]. The apparent lack of need for monitoring
BU levels when the oral dose was reduced to 14 mg/kg
(or the i.v. dose was reduced to 11.2 mg/kg) in this
population, as well as the apparent preservation of a po-
tent antilymphoma effect with this regimen, suggest
that this was a reasonable regimen to study in patients
with relapsedHIV-related lymphoma. This AIDSMa-
lignancy Consortium–coordinated trial demonstrates
that this regimen is feasible and remarkably well toler-
ated by patients in a multicenter setting. Comparable
PFS probabilities to those reported by Serrano et al.
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Figure 2.Distribution levels of CD4 counts (A) and HIV RNA copies/mL (B) by time interval in 20 patients who received
AuSCT for recurrent HIV-associatedNHL orHL. The upper and lower bars of each box plot represent the maximum and
minimum values, respectively. The horizontal bar at the center of each boxplot represents the median values, and the top
(Q3) and bottom (Q1) of each box plot represent the 75th and 25th percentiles, respectively.
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Investigator
Disease
(patients receiving
AuSCT)
Preparative
regimen
PBSC,
median number
(CD341 cells/kg)
ANC . 0.5,
days (range) TRM PFS/EFS* OS*
Krishnan et al. [13] NHL (n 5 18) CBV (n 5 17) 10.6  106 11 (9-23) 1/20 (5%) 85%
at 32 months
85% at
32 months
HL (n 5 2) fTBI/CY/VP-16
(n 5 3)
Serrano et al. [14] NHL (n 5 7) BEAM (n 5 10) 4.7  106 16 (9-33) 0/11 (0%) 65%
at 30 months
65% at
30 months
HL (n 5 4) BEAC (n 5 1)
Gabarre et al. [15] NHL (n 5 8) BEAM (n 5 5) 5.8  106 12 (7-14) 0/14 (0%) 4/14 in CCR
at 26 months
5/14 at
32 months
HL (n 5 6) TBI/CY (n 5 5)
Other (n 5 4)
Re et al. [16] NHL (n 5 8) BEAM 6.8  106 10 (8-10) 0/16 (0%) 6/10 in CCR
at 8 months
6/10 at
8 months
HL (n 5 8)
BEAC indicates BCNU, etoposide, cytarabine; cyclophosphamide; fTBI, fractionated total body irradiation; CBV, cyclophosphamide, BCNU,
etoposide (VP-16); PBSC, peripheral blood stem cells; TRM, transplantation-related mortality; CCR, continuous complete remission.
*PFS/OS of patients receiving AuSCT (median follow-up)[14], Gabarre et al. [15], and Re et al. [16] demonstrate
that the dose-adjusted BU and Cy preparative regimen
is an effective strategy in the management of relapsed
HIV-associated lymphoma. The apparently superior
survival outcomes reported by Krishnan et al. [13]
may reflect a different patient population in terms of dis-
ease status, previous treatment, HAART regimen, or
other factors. Given the similar survival outcomes in
our study to those of the other transplantation studies,
it is not clear that the preparative regimen is a determin-
ing factor in terms of relapse probability and survival.
The fact that only 20 of the 27 patients enrolled in
this trial received an AuSCT (because in 4 cases of
early disease progression) underscores the tenuous re-
mission status of many patients with HIV-associated
lymphoma and highlights the importance of carefully
selecting patients whose HIV infection is under rea-
sonable control and whose disease is responding to sal-
vage therapy. The exclusion of patients primarily from
early disease progression also was noted by Re et al.
[16] and Serrano et al. [14]; only 10 of 16 (63%) and
11 of 14 (79%) patients, respectively, in those 2 series
received an AuSCT. These statistics also likely under-
estimate the number of patients who would not receive
a transplant if the trials enrolled patients at the time of
relapse and before salvage therapy.
Dose-reduced BU and CY and AuSCT for HIV-
associated lymphoma is associated with an acceptable
safety profile. Among the 20 patients who received
an AuSCT, only 1 death (5%) was attributable to the
regimen (hepatic VOD and multiorgan failure). Aside
from the expected grade IV hematologic toxicities and
febrile neutropenia in 6 of the 20 patients (30%),
only 4 other instances of grade IV toxicity occurred
(Table 2). Immune reconstitution in this population
of relatively older individuals (median age 42; range,up to 60 years) also was favorable. No deaths attribut-
able to infection occurred. CD41 cell counts reached
a nadir at approximately 2months posttransplantation,
then recovered to baseline levels (on average in the
group as a whole) by day 1260.
The antitumor efficacy of the BU and CY regimen
was well demonstrated. Ten of the 20 patients were in
CR at a median of 23 weeks (range, 4-1201 weeks)
posttransplantation. The event-free and OS probabil-
ities of 49.5% and 74.4% at 6 months are similar to
those in patients receiving AuSCT for recurrent non-
HIV–associated, chemosensitive, aggressive NHL or
HL [1,2,33,34]. Based on the small number of patients
in this and other published series and the lack of data
from a prospective randomized trial, a conclusion can-
not be reached regarding the optimal preparative reg-
imen for AuSCT. Nonetheless, dose-reduced BU and
CY is clearly well tolerated and has substantial antitu-
mor activity in patients with HIV-associated aggres-
sive NHL and HL, and should be further evaluated
in a larger prospective clinical trial. Larger studies
would also provide more insight into various parame-
ters that are likely important in influencing patient
outcome, such as type of HAART, CD41 cell count
andHIVVL before AuSCT, Epstein-Barr virus status,
and tumor histology.
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